{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:49:49Z","timestamp":1793742589640,"version":"4.6.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>Cervical intraepithelial neoplasia grade 2 (CIN 2) is an equivocal diagnosis with high interobserver variation. Owing to high regression rates of 50%, many countries recommend active surveillance of CIN 2, especially in women younger than age 25\u201330 years, where regression rates are even higher (ie, 60%). Additionally, excisional treatment is associated with increased risk of reproductive harm, particularly preterm birth. Active surveillance typically consists of semi-annual follow-up visits for up to 2 years, including colposcopy and either cytology, testing for human papillomavirus, or both. Excisional treatment is recommended for progression or persistent disease after 2 years. Because active surveillance in younger women is relatively new, knowledge on subsequent risk of cervical cancer is limited. Considering human papillomavirus latency, women undergoing active surveillance might be at higher risk of cervical cancer than women undergoing excisional treatment. Furthermore, there are limited data describing preferences of women for the management of CIN 2, and it is also unclear how active surveillance may affect planning for future pregnancy. In this context, biomarkers for risk stratification of CIN 2 into either high or low probability of progression would allow for targeted treatment. Currently, immunohistochemical staining for p16 is used to clarify the histologic diagnosis, but whether it or other biomarkers can be used for risk-stratification in clinical management of women with CIN 2 remains unknown. In conclusion, active surveillance of CIN 2 needs further investigation, including understanding the long-term cervical cancer risk and evaluation of markers that may enable risk stratification of CIN 2.<\/jats:p>","DOI":"10.1097\/aog.0000000000004705","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T17:08:12Z","timestamp":1646932092000},"page":"680-686","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Known Benefits and Unknown Risks of Active Surveillance of Cervical Intraepithelial Neoplasia Grade 2"],"prefix":"10.1097","volume":"139","author":[{"given":"Kathrine D.","family":"Lycke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone K.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti E.","family":"Gravitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"R1-20260916","first-page":"2157","article-title":"Effect of organized screening on incidence and mortality of cervical cancer in Denmark","volume":"49","author":"Lynge","year":"1989","journal-title":"Cancer Res"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.12.013","article-title":"Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review","volume":"127","author":"Jansen","year":"2020","journal-title":"Eur J Cancer"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2016.290","article-title":"Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study","volume":"115","author":"Landy","year":"2016","journal-title":"Br J Cancer"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1471-0528.16081","article-title":"Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study","volume":"127","author":"Skorstengaard","year":"2020","journal-title":"BJOG"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/LGT.0000000000000604","article-title":"The natural history of cervical intraepithelial neoplasia grades 1, 2, and 3: a systematic review and meta-analysis","volume":"25","author":"Loopik","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/AOG.0000000000000174","article-title":"Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis","volume":"123","author":"Conner","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","article-title":"CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples","volume":"26","author":"Carreon","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e3181e8b2c4","article-title":"Using biomarkers as objective standards in the diagnosis of cervical biopsies","volume":"34","author":"Galgano","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R12-20260916","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PGP.0b013e31826916c7","article-title":"The lower anogenital squamous terminology standardization Project for HPV-associated lesions","volume":"32","author":"Darragh","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5858\/arpa.2019-0241-OA","article-title":"Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities implications for LAST terminology","volume":"144","author":"Castle","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/01443615.2017.1316973","article-title":"Conservative management of CIN2: national audit of British society for colposcopy and cervical pathology members' opinion","volume":"38","author":"Macdonald","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1471-0528.2006.01107.x","article-title":"Precancerous changes in the cervix and risk of subsequent preterm birth","volume":"114","author":"Bruinsma","year":"2006","journal-title":"BJOG"},{"key":"R25-20260916","doi-asserted-by":"crossref","first-page":"769.e1","DOI":"10.1016\/j.ajog.2015.01.010","article-title":"Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2","volume":"212","author":"Wilkinson","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R26-20260916","doi-asserted-by":"crossref","first-page":"20847","DOI":"10.1038\/srep20847","article-title":"Evidence of disrupted high-risk human papillomavirus DNA in morphologically normal cervices of older women","volume":"6","author":"Leonard","year":"2016","journal-title":"Sci Rep"},{"key":"R27-20260916","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pvr.2019.02.004","article-title":"Whole tissue cervical mapping of HPV infection: molecular evidence for focal latent HPV infection in humans","volume":"7","author":"Hammer","year":"2019","journal-title":"Papillomavirus Res"},{"key":"R28-20260916","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1158\/0008-5472.CAN-12-2635","article-title":"Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women","volume":"72","author":"Rositch","year":"2012","journal-title":"Cancer Res"},{"key":"R29-20260916","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/infdis\/jiaa557","article-title":"Rates of new human papillomavirus detection and loss of detection in middle-aged women by recent and past sexual behavior","volume":"223","author":"Paul","year":"2021","journal-title":"J Infect Dis"},{"key":"R30-20260916","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2021.01.010","article-title":"Active surveillance as a management option for cervical intraepithelial neoplasia 2: an online experimental study","volume":"161","author":"Dodd","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R31-20260916","article-title":"Understanding women's choices for management of cervical intraepithelial neoplasia 2 (CIN2): qualitative analysis of a randomised experimental study","author":"Keers","year":"2021","journal-title":"Aust N Z J Obs Gynaecol"},{"key":"R32-20260916","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2147\/IJWH.S208257","article-title":"Patients with cervical intraepithelial neoplasms show different states of health-related quality of life and different coping styles depending on the choice of therapy: findings from the CIN study","volume":"11","author":"Kl\u00fcgel","year":"2019","journal-title":"Int J Womens Health"},{"key":"R33-20260916","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/ajo.12633","article-title":"Initial observation of CIN2 does not appear to reduce quality of life in women under 25 years of age","volume":"57","author":"Taghavi","year":"2017","journal-title":"Aust N Z J Obs Gynaecol"},{"key":"R34-20260916","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/modpathol.2015.52","article-title":"Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM","volume":"28","author":"Griffin","year":"2015","journal-title":"Mod Pathol"},{"key":"R35-20260916","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/cam4.2855","article-title":"Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions","volume":"9","author":"Leeman","year":"2020","journal-title":"Cancer Med"},{"key":"R36-20260916","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1097\/PAS.0000000000000498","article-title":"Investigating diagnostic problems of CIN 1 and 2 associated with high-risk HPV by combining the novel molecular biomarker PanHPV E4 with p16ink4a","volume":"39","author":"Van Baars","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R37-20260916","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ijc.33566","article-title":"Classification of high-grade cervical intraepithelial neoplasia by p16ink4a, Ki-67, HPV E4 and FAM19A4\/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management","volume":"149","author":"Vink","year":"2021","journal-title":"Int J Cancer"},{"key":"R38-20260916","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ebiom.2019.10.053","article-title":"The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis","volume":"50","author":"Bowden","year":"2019","journal-title":"EbioMedicine"},{"key":"R39-20260916","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41416-019-0593-4","article-title":"Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis","volume":"121","author":"Kelly","year":"2019","journal-title":"Br J Cancer"},{"key":"R40-20260916","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R41-20260916","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/cid\/ciz677","article-title":"Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia","volume":"70","author":"Louvanto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R42-20260916","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/ijc.31883","article-title":"Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types","volume":"144","author":"Sand","year":"2019","journal-title":"Int J Cancer"},{"key":"R43-20260916","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R44-20260916","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R45-20260916","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","article-title":"Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women","volume":"116","author":"Moscicki","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R46-20260916","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-world effectiveness of human papillomavirus vaccination against cervical cancer","volume":"113","author":"Kjaer","year":"2021","journal-title":"J Natl Cancer Inst"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:56Z","timestamp":1789556636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004705","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"2021-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}